Description of Operations and Summary of Significant Accounting Policies (Details) $ in Millions			12 Months Ended
	Jun. 02, 2014	Jun. 01, 2014 USD ($)	Dec. 31, 2015
Business Separation
Cash, cash equivalents and marketable securities contributed to Theravance Biopharma		$ 393.0
Number of ordinary shares of Theravance Biopharma issued for every share of Theravance	0.286
GSK | LABA collaboration and Strategic Alliance agreements
Description of Operations and Summary of Significant Accounting Policies
Percentage of economic interest in any future payments made under the agreements			15.00%